Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.59 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.59 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14597743 | 0.81 | KDM4C (0.60) | SCN9ASCN10A | |
| SCHEMBL5474090 | 0.76 | BACE1 (0.51) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL16967275 | 0.75 | SCN9A (1.00) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL16967132 | 0.75 | SCN9A (1.00) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL13142979 | 0.74 | MRGPRX4 (0.52) | MRGPRX4 | |
| SCHEMBL1285735 | 0.74 | BACE1 (0.56) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL16966661 | 0.73 | SCN9A (1.00) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL27902504 | 0.73 | BACE1 (0.58) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL30387658 | 0.73 | BACE1 (0.58) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL178271 | 0.72 | LMNA (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | PFIZER INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004774-A1 | Cept inhibitors and metabolites thereof | CETP, LCAT, MTTP | SCN9A 4543/4885SCN7A 4380/4885KCNH2 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.